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Colorectal  cancer:  From  the  laboratory  to the patient,
a now indispensable  step pa
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MCáncer  colorrectal:  del  laboratorio  al
Colorectal  cancer  is  the  third  most  common  cancer  in  men
and  the  second  in  women  worldwide,  whereas  gastric  can-
cer  is  the  fourth  most  frequent  cancer  in  men  and  the
ﬁfth  in  women.1 In  both  cases,  the  differences  in  incidence
among  diverse  geographic  areas  are  very  substantial  and
are  clearly  associated  with  dietary  and  environmental  fac-
tors.  Different  Latin  American  registries  show  colorectal
cancer  incidence  to  be  below  that  of  other  regions,  par-
ticularly  in  the  more  developed  countries.2 Unfortunately,
whereas  the  incidence  of  this  cancer  is  decreasing  in  the
Western  world,  Latin  American  countries  have  registered
signiﬁcant  increases  in  colorectal  cancer  mortality  rates
within  the  last  few  years.2 The  incidence  of  gastric  cancer
is  particularly  elevated  in  some  Latin  American  countries,
such  as  Chile  or  Costa  Rica,  but  it  is  much  lower  in  other
regions,  such  as  Mexico  or  Puerto  Rico;3 Helicobacter  pylori
infection  rates  and  tobacco  consumption  have  been  deter-
minants  for  explaining  the  majority  of  these  differences.
Fortunately,  the  incidence  of  gastric  cancer  is  progressively
decreasing  in  Latin  America,  as  in  many  other  parts  of  the
world.
Much  has  been  learned  in  recent  years  about  the  molec-
ular  mechanisms  involved  in  the  carcinogenic  processes  of
these  tumors.  This  is  of  the  utmost  importance,  given  that
such  knowledge  is  revolutionizing  therapeutic  approaches,
enabling  targeted  treatments  that  are  more  efﬁcacious  in
determined  groups  of  cancers  with  speciﬁc  alterations  in
some  pathways  instead  of  others  the  so-called  precision
medicine.
Colorectal  cancer  develops  through  a  process  of  numer-
ous  stages,  known  as  the  adenoma-carcinoma  sequence,
proposed  by  Fearon  and  Vogelstein  more  than  two  decades
ago.4 During  this  process,  genetic  and  epigenetic  alterations
accumulate  in  genes  that  are  crucial  for  controlling  cell
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rowth  and  differentiation.  Genomic  instability  is  charac-
eristic  of  colorectal  cancer  and  affects  the  entire  genome,
mplying  the  loss  of  DNA  integrity,  which  accelerates  the
rocess  of  mutation  accumulation.  This  instability  can  be
hromosomal  (CIN)  or  involve  microsatellites  (MSI).  Tumors
ith  CIN  are  the  most  common  and  present  with  loss  of
eterozygosity,  frequent  cytogenetic  alterations,  and  allelic
oss.5 This  process  is  known  as  the  suppressor  pathway
f  colorectal  cancer.  Tumors  that  present  with  CIN  also
how  inactivation  of  oncosuppressor  genes  such  as  APC,
53,  DCC,  SMAD2, and  SMAD4. However,  the  genes  that
nable  this  instability  are  not  yet  well  established.  Tumors
ith  MSI  develop  as  a  result  of  the  disruption  of  the  DNA
ismatch  repair  (MMR)  system.  The  function  of  the  pro-
eins  encoded  by  the  genes  of  this  system  (MLH1,  MSH2,
SH3,  MSH6,  PMS2)  is  to  repair  the  mismatches  between
ases  that  are  habitually  and  periodically  produced  during
NA  replication.6 When  these  genes  do  not  function,  muta-
ions  accumulate  along  the  genome,  especially  in  repetitive
ucleotide  sequences  known  as  microsatellites.  They  are
ocated  in  non-encoding  regions  and  also  in  gene-codifying
equences  such  as  IGFR2,  TGFˇR2,  BAX, or  MSH6  that  con-
rol  important  cell  mechanisms.  In  the  large  majority  of
ases,  the  presence  of  MSI  is  due  to  hypermethylation  of
he  MLH1  promoter  gene  with  the  subsequent  inactivation
f  gene  transcription  and  the  loss  of  protein  expression.7
LH1  methylation  alteration  is  one  of  the  most  solid  proves
f  the  involvement  of  an  epigenetic  defect  in  the  devel-
pment  of  CRC  and  is  responsible  for  80%  of  the  cases  of
SI.
The  use  of  molecular  alterations  for  guiding  chemother-
peutic  treatments  is  now  a  reality.  For  example,  the
pithelial  growth  factor  receptor  (EGFR)  inhibitor  cetuximab
s  only  indicated  in  the  treatment  of  CRC  in  patients  that  do
ot  have  tumors  with  K-Ras  mutations,  because  these  muta-
ions  prevent  the  drug  from  responding.  In  addition,  the
se  of  epigenetic  targets  for  developing  new  chemotherapy
reatments  is  emerging  as  a  strategy  with  great  possibilities,
ecause  in  principle,  epigenetic  alterations  are  potentially
 by Masson Doyma México S.A. All rights reserved.
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eversible.  Thus  the  drug  would  revert  the  genetic  repres-
ion  of  oncosuppressor  genes.  The  most  widely  studied  of
hese  drugs  are  the  demethylating  agents  that  inactivate  the
NA  methyltransferases  (DNMTs).  The  two  DNMT  inhibitors,
zacitidine  and  decitabine,  are  currently  approved  by  the
.S.  Food  and  Drug  Administration  for  use  in  patients  with
ematologic  diseases,  and  their  use  in  different  cancers,
ncluding  colon  cancer,  is  being  evaluated.
The  capacity  to  systematically  evaluate  these  types  of
olecular  alterations  in  tumors  and  progressively  incorpo-
ate  them  into  the  medical  routine  is  of  great  importance  for
ppropriate  patient  attention.  The  study  of  these  mutations
as  special  relevance  in  the  case  of  cancers  diagnosed  in
atin  America,  not  only  for  the  importance  of  the  above-
entioned,  but  also  because  there  is  a  total  absence  of
olecular  data  from  patients  of  this  region.  It  is  extremely
ratifying  to  ﬁnally  have  contributions  such  as  those  of
alacio-Rúa  et  al.  in  this  edition  of  the  Journal.  The  authors
xamined  59  gastric  and  colorectal  tumors  for  the  most  com-
only  described  mutations  of  the  APC, p53, and  KRAS  genes.
he  number  of  mutations  found  was  relatively  lower  than
hat  reported  in  case  series  from  other  areas  of  the  world,
hich  may  be  due  to  the  fact  that  the  study  was  limited  to
he  APC  and  p53  gene  regions  that  usually  house  the  majority
f  pathogenic  mutations.  Thus,  it  cannot  be  ruled  out  that
ome  mutations  were  not  detected  because  they  were  out-
ide  of  these  regions,  but  it  is  also  possible,  as  the  authors
ointed  out,  that  there  is  a  differential  incidence  that  can
epend  on  many  factors  that  have  yet  to  be  identiﬁed.  At
ny  rate,  this  study  not  only  conﬁrms  the  ability  to  conduct
his  type  of  analysis  in  Latin  America,  but  it  also  paves  the
ay  for  a  future  study  with  a  higher  number  of  cases  and
xpanded  coverage  of  gene  regions  that  will  undoubtedly
e  of  tremendous  value.  The  present  work  already  helps  to
reate  awareness  of  the  importance  of  these  studies,  givenEDITORIAL
hat  they  have  direct  implications  in  the  choice  of  drugs  to
e  used  in  treating  these  cancers.8
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